Details of the Drug

General Information of Drug (ID: DMR6QH0)

Drug Name
Venlafaxine
Synonyms
Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 277.4
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 152.6 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 352.8 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 10% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [5]
Elimination
4.6% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [5]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.5868 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.73% [5]
Vd
The volume of distribution (Vd) of drug is 7.5 +/- 3.7 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 572 mg/mL [4]
Chemical Identifiers
Formula
C17H27NO2
IUPAC Name
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
Canonical SMILES
CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
InChI
InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
InChIKey
PNVNVHUZROJLTJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5656
ChEBI ID
CHEBI:9943
CAS Number
93413-69-5
DrugBank ID
DB00285
TTD ID
D0P1UX
VARIDT ID
DR00450
INTEDE ID
DR1679
ACDINA ID
D00725

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [9]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Venlafaxine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aprepitant DM053KT Moderate Decreased metabolism of Venlafaxine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Venlafaxine and Sertraline. Depression [6A70-6A7Z] [57]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Venlafaxine and Trimipramine. Depression [6A70-6A7Z] [57]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Venlafaxine and Cyclobenzaprine. Depression [6A70-6A7Z] [57]
Imipramine DM2NUH3 Major Additive serotonergic effects by the combination of Venlafaxine and Imipramine. Depression [6A70-6A7Z] [57]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Venlafaxine and Fluoxetine. Depression [6A70-6A7Z] [57]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Venlafaxine and Nortriptyline. Depression [6A70-6A7Z] [57]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Venlafaxine and Vilazodone. Depression [6A70-6A7Z] [57]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Venlafaxine and Nefazodone. Depression [6A70-6A7Z] [57]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Venlafaxine and Paroxetine. Depression [6A70-6A7Z] [57]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Venlafaxine and Selegiline. Depression [6A70-6A7Z] [58]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Venlafaxine and Vortioxetine. Depression [6A70-6A7Z] [57]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Venlafaxine and Duloxetine. Depression [6A70-6A7Z] [57]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Venlafaxine and Isocarboxazid. Depression [6A70-6A7Z] [58]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Venlafaxine and Milnacipran. Depression [6A70-6A7Z] [57]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Venlafaxine and Escitalopram. Depression [6A70-6A7Z] [59]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Venlafaxine and Tranylcypromine. Depression [6A70-6A7Z] [58]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Venlafaxine and Desvenlafaxine. Depression [6A70-6A7Z] [57]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Venlafaxine and Phenelzine. Depression [6A70-6A7Z] [58]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Venlafaxine and Clomipramine. Depression [6A70-6A7Z] [57]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Venlafaxine and Trazodone. Depression [6A70-6A7Z] [57]
Amitriptyline DMK7F9S Major Additive serotonergic effects by the combination of Venlafaxine and Amitriptyline. Depression [6A70-6A7Z] [57]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Venlafaxine and Amoxapine. Depression [6A70-6A7Z] [57]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Venlafaxine and Mirtazapine. Depression [6A70-6A7Z] [57]
Protriptyline DMNHTZI Major Additive serotonergic effects by the combination of Venlafaxine and Protriptyline. Depression [6A70-6A7Z] [57]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Venlafaxine and Doxepin. Depression [6A70-6A7Z] [57]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Venlafaxine and Maprotiline. Depression [6A70-6A7Z] [57]
⏷ Show the Full List of 27 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Venlafaxine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Venlafaxine and Methylene blue. Acquired methaemoglobinaemia [3A93] [60]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Ivosidenib. Acute myeloid leukaemia [2A60] [61]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Midostaurin. Acute myeloid leukaemia [2A60] [62]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Idarubicin. Acute myeloid leukaemia [2A60] [62]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Daunorubicin. Acute myeloid leukaemia [2A60] [62]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Arn-509. Acute myeloid leukaemia [2A60] [63]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Gilteritinib. Acute myeloid leukaemia [2A60] [64]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Venlafaxine and Oliceridine. Acute pain [MG31] [65]
Epinephrine DM3KJBC Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [66]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [62]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Tacrine. Alzheimer disease [8A20] [62]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Galantamine. Alzheimer disease [8A20] [62]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Rivastigmine. Alzheimer disease [8A20] [62]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Donepezil. Alzheimer disease [8A20] [62]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Venlafaxine and Metronidazole. Amoebiasis [1A36] [56]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Venlafaxine and Inotersen. Amyloidosis [5D00] [67]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Ivabradine. Angina pectoris [BA40] [63]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Bepridil. Angina pectoris [BA40] [62]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Dronedarone. Angina pectoris [BA40] [62]
Nifedipine DMSVOZT Moderate Decreased metabolism of Venlafaxine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [56]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Venlafaxine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [68]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Venlafaxine when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [69]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Promazine. Appearance/behaviour symptom [MB23] [62]
Posaconazole DMUL5EW Moderate Decreased metabolism of Venlafaxine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [56]
Levalbuterol DM5YBO1 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Levalbuterol. Asthma [CA23] [66]
Terbutaline DMD4381 Moderate Additive hypertensive effects by the combination of Venlafaxine and Terbutaline. Asthma [CA23] [66]
Pirbuterol DMI5678 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Pirbuterol. Asthma [CA23] [66]
Ephedrine DMMV0KW Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Ephedrine. Asthma [CA23] [66]
Salbutamol DMN9CWF Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Salbutamol. Asthma [CA23] [66]
Formoterol DMSOURV Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Formoterol. Asthma [CA23] [66]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Venlafaxine and Desipramine. Attention deficit hyperactivity disorder [6A05] [57]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Venlafaxine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Venlafaxine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Venlafaxine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [62]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Venlafaxine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [70]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Venlafaxine caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Venlafaxine and Linezolid. Bacterial infection [1A00-1C4Z] [71]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Norfloxacin. Bacterial infection [1A00-1C4Z] [70]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Levofloxacin. Bacterial infection [1A00-1C4Z] [70]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Venlafaxine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [62]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Venlafaxine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [56]
Retigabine DMGNYIH Moderate Antagonize the effect of Venlafaxine when combined with Retigabine. Behcet disease [4A62] [69]
Lamotrigine DM8SXYG Moderate Antagonize the effect of Venlafaxine when combined with Lamotrigine. Bipolar disorder [6A60] [69]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Venlafaxine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [72]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Loperamide. Bowel habit change [ME05] [73]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Eribulin. Breast cancer [2C60-2C6Y] [62]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Lapatinib. Breast cancer [2C60-2C6Y] [62]
Tucatinib DMBESUA Moderate Decreased metabolism of Venlafaxine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Palbociclib DMD7L94 Moderate Decreased metabolism of Venlafaxine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Tamoxifen. Breast cancer [2C60-2C6Y] [62]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Venlafaxine and Toremifene. Breast cancer [2C60-2C6Y] [62]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Venlafaxine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [74]
Pseudoephedrine DMIVJ0D Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Pseudoephedrine. Breathing abnormality [MD11] [66]
Mannitol DMSCDY9 Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Mannitol. Bronchiectasis [CA24] [75]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Venlafaxine and Grepafloxacin. Bronchitis [CA20] [70]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Venlafaxine and Sotalol. Cardiac arrhythmia [BC9Z] [62]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [76]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Venlafaxine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [66]
Vilanterol DMF5EK1 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [66]
Salmeterol DMIEU69 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [66]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Venlafaxine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [66]
Arformoterol DMYM974 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [66]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Venlafaxine and Phenylbutazone. Chronic pain [MG30] [67]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Venlafaxine and Ketoprofen. Chronic pain [MG30] [67]
Morphine DMRMS0L Moderate Additive serotonergic effects by the combination of Venlafaxine and Morphine. Chronic pain [MG30] [65]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Venlafaxine when combined with Levetiracetam. Chronic pain [MG30] [69]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Venlafaxine and Levomilnacipran. Chronic pain [MG30] [57]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Venlafaxine and Anisindione. Coagulation defect [3B10] [67]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Venlafaxine and Regorafenib. Colorectal cancer [2B91] [67]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Oxaliplatin. Colorectal cancer [2B91] [62]
Isoproterenol DMK7MEY Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Isoproterenol. Conduction disorder [BC63] [66]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Venlafaxine and Olopatadine. Conjunctiva disorder [9A60] [77]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Propofol. Corneal disease [9A76-9A78] [78]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Sevoflurane. Corneal disease [9A76-9A78] [62]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Venlafaxine and Alfentanil. Corneal disease [9A76-9A78] [57]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Probucol. Coronary atherosclerosis [BA80] [62]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Venlafaxine and Ardeparin. Coronary thrombosis [BA43] [67]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Venlafaxine and Methadone. Cough [MD12] [62]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Venlafaxine and Dextromethorphan. Cough [MD12] [57]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Clofazimine. Crohn disease [DD70] [79]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Venlafaxine and Pasireotide. Cushing syndrome [5A70] [62]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Osilodrostat. Cushing syndrome [5A70] [63]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Venlafaxine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [56]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Venlafaxine and Ethanol. Cystitis [GC00] [77]
MK-8228 DMOB58Q Moderate Decreased metabolism of Venlafaxine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [56]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Venlafaxine and Danaparoid. Deep vein thrombosis [BD71] [67]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Venlafaxine and Rivaroxaban. Deep vein thrombosis [BD71] [67]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Venlafaxine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [66]
LEVONORDEFRIN DMWDJ0H Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and LEVONORDEFRIN. Discovery agent [N.A.] [66]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [62]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Deutetrabenazine. Dystonic disorder [8A02] [80]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Ingrezza. Dystonic disorder [8A02] [81]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Venlafaxine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [57]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Venlafaxine when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [69]
Felbamate DM1V5ZS Moderate Antagonize the effect of Venlafaxine when combined with Felbamate. Epilepsy/seizure [8A61-8A6Z] [69]
Oxcarbazepine DM5PU6O Moderate Antagonize the effect of Venlafaxine when combined with Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [69]
Mephenytoin DM5UGDK Moderate Antagonize the effect of Venlafaxine when combined with Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [69]
Methsuximide DM6L5VO Moderate Antagonize the effect of Venlafaxine when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [69]
Gabapentin DM6T924 Moderate Antagonize the effect of Venlafaxine when combined with Gabapentin. Epilepsy/seizure [8A61-8A6Z] [69]
Valproate DMCFE9I Moderate Antagonize the effect of Venlafaxine when combined with Valproate. Epilepsy/seizure [8A61-8A6Z] [69]
Ethosuximide DMDZ9LT Moderate Antagonize the effect of Venlafaxine when combined with Ethosuximide. Epilepsy/seizure [8A61-8A6Z] [69]
Cenobamate DMGOVHA Moderate Increased metabolism of Venlafaxine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Venlafaxine when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [69]
Stiripentol DMMSDOY Moderate Decreased metabolism of Venlafaxine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [56]
Phenacemide DMOHS9P Moderate Antagonize the effect of Venlafaxine when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [69]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Venlafaxine when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [69]
Brivaracetam DMSEPK8 Moderate Antagonize the effect of Venlafaxine when combined with Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [69]
Lacosamide DMVM6QR Moderate Antagonize the effect of Venlafaxine when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [69]
Ethotoin DMXWOCP Moderate Antagonize the effect of Venlafaxine when combined with Ethotoin. Epilepsy/seizure [8A61-8A6Z] [69]
Vigabatrin DMYT0OG Moderate Antagonize the effect of Venlafaxine when combined with Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [69]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [69]
Ethacrynic acid DM60QMR Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Ethacrynic acid. Essential hypertension [BA00] [75]
Bendroflumethiazide DM7EVLC Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Bendroflumethiazide. Essential hypertension [BA00] [75]
Mephentermine DMFJH5Q Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Mephentermine. Essential hypertension [BA00] [66]
Benzthiazide DMQWZ0H Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Benzthiazide. Essential hypertension [BA00] [75]
Oxymetazoline DM8ZXT6 Moderate Additive hypertensive effects by the combination of Venlafaxine and Oxymetazoline. Eyelid inflammatory disorder [9A02] [66]
Phenylephrine DMZHUO5 Moderate Additive hypertensive effects by the combination of Venlafaxine and Phenylephrine. Faecal incontinence [ME07] [66]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Venlafaxine and Mefenamic acid. Female pelvic pain [GA34] [67]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Venlafaxine and Tazemetostat. Follicular lymphoma [2A80] [67]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Solifenacin. Functional bladder disorder [GC50] [62]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Pentamidine. Fungal infection [1F29-1F2F] [62]
Terbinafine DMI6HUW Moderate Decreased metabolism of Venlafaxine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [83]
Miconazole DMPMYE8 Moderate Decreased metabolism of Venlafaxine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [56]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Venlafaxine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [56]
Cimetidine DMH61ZB Minor Decreased metabolism of Venlafaxine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [84]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Venlafaxine and Cisapride. Gastro-oesophageal reflux disease [DA22] [62]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [62]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Venlafaxine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [67]
Acetazolamide DM1AF5U Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Acetazolamide. Glaucoma [9C61] [75]
Methazolamide DM7J2TA Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Methazolamide. Glaucoma [9C61] [75]
Dipivefrin DMH5W0G Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Dipivefrin. Glaucoma [9C61] [66]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Dichlorphenamide. Glaucoma [9C61] [75]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Venlafaxine and Sulfinpyrazone. Gout [FA25] [67]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Venlafaxine and Ergotamine. Headache [8A80-8A84] [57]
Spironolactone DM2AQ5N Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Spironolactone. Heart failure [BD10-BD1Z] [75]
Triamterene DM2HU9I Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Triamterene. Heart failure [BD10-BD1Z] [75]
Dobutamine DMD1B8Z Moderate Additive hypertensive effects by the combination of Venlafaxine and Dobutamine. Heart failure [BD10-BD1Z] [66]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Chlorothiazide. Heart failure [BD10-BD1Z] [75]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Furosemide. Heart failure [BD10-BD1Z] [75]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Amiloride. Heart failure [BD10-BD1Z] [75]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Bumetanide. Heart failure [BD10-BD1Z] [75]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [75]
Boceprevir DMBSHMF Moderate Decreased metabolism of Venlafaxine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [56]
Telaprevir DMMRV29 Moderate Decreased metabolism of Venlafaxine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [56]
Tetrahydrozoline DMT57WC Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Tetrahydrozoline. Herpes simplex infection [1F00] [66]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Venlafaxine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [56]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Venlafaxine and Procarbazine. Hodgkin lymphoma [2B30] [58]
Delavirdine DM3NF5G Moderate Decreased metabolism of Venlafaxine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Venlafaxine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [85]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Venlafaxine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Venlafaxine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [86]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Venlafaxine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [87]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [62]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Venlafaxine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Darunavir DMN3GCH Moderate Decreased metabolism of Venlafaxine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Atazanavir DMSYRBX Moderate Decreased metabolism of Venlafaxine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Ritonavir DMU764S Moderate Decreased metabolism of Venlafaxine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Venlafaxine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [56]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Venlafaxine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [56]
Verapamil DMA7PEW Moderate Decreased metabolism of Venlafaxine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [56]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Venlafaxine caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [56]
Methoxamine DMF5XQH Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Methoxamine. Hypertension [BA00-BA04] [66]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Indapamide. Hypertension [BA00-BA04] [75]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Trichlormethiazide. Hypertension [BA00-BA04] [75]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Hydrochlorothiazide. Hypertension [BA00-BA04] [75]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Venlafaxine and Dipyridamole. Hypertension [BA00-BA04] [67]
Metaraminol DMWIX23 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Metaraminol. Hypotension [BA20-BA21] [66]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Venlafaxine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [74]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Venlafaxine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [88]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Venlafaxine and Polyethylene glycol. Irritable bowel syndrome [DD91] [62]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Phenolphthalein. Irritable bowel syndrome [DD91] [62]
Naphazoline DMJFZDL Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Naphazoline. Itching [1F28-1G07] [66]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Venlafaxine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [63]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Venlafaxine and Crizotinib. Lung cancer [2C25] [89]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Venlafaxine and Porfimer Sodium. Lung cancer [2C25] [90]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Venlafaxine and Ceritinib. Lung cancer [2C25] [62]
PF-06463922 DMKM7EW Moderate Increased metabolism of Venlafaxine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [91]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Venlafaxine and Osimertinib. Lung cancer [2C25] [92]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Venlafaxine and Selpercatinib. Lung cancer [2C25] [63]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Venlafaxine and Lumefantrine. Malaria [1F40-1F45] [56]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Venlafaxine and Halofantrine. Malaria [1F40-1F45] [93]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Venlafaxine and Chloroquine. Malaria [1F40-1F45] [94]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Quinine. Malaria [1F40-1F45] [62]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Primaquine. Malaria [1F40-1F45] [62]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [63]
Idelalisib DM602WT Moderate Decreased metabolism of Venlafaxine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
IPI-145 DMWA24P Moderate Decreased metabolism of Venlafaxine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [95]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Venlafaxine and Acalabrutinib. Mature B-cell lymphoma [2A85] [67]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Venlafaxine and Ibrutinib. Mature B-cell lymphoma [2A85] [67]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Venlafaxine and Ponatinib. Mature B-cell lymphoma [2A85] [67]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Vemurafenib. Melanoma [2C30] [62]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and LGX818. Melanoma [2C30] [96]
Danazol DML8KTN Moderate Decreased metabolism of Venlafaxine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [56]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Venlafaxine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [97]
Zolmitriptan DM1IB4Q Major Additive serotonergic effects by the combination of Venlafaxine and Zolmitriptan. Migraine [8A80] [57]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Venlafaxine and Almogran. Migraine [8A80] [57]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Venlafaxine and Frovatriptan. Migraine [8A80] [57]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Venlafaxine and Rizatriptan. Migraine [8A80] [57]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Venlafaxine and Naratriptan. Migraine [8A80] [57]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Venlafaxine and Sumatriptan. Migraine [8A80] [57]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Venlafaxine and Exjade. Mineral absorption/transport disorder [5C64] [67]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Venlafaxine and Flibanserin. Mood disorder [6A60-6E23] [98]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Venlafaxine and Panobinostat. Multiple myeloma [2A83] [99]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Venlafaxine and Thalidomide. Multiple myeloma [2A83] [100]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Siponimod. Multiple sclerosis [8A40] [56]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Fingolimod. Multiple sclerosis [8A40] [62]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Venlafaxine and Ozanimod. Multiple sclerosis [8A40] [58]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Romidepsin. Mycosis fungoides [2B01] [62]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Venlafaxine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [56]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Venlafaxine and Nilotinib. Myeloproliferative neoplasm [2A20] [62]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Venlafaxine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [67]
Imatinib DM7RJXL Moderate Decreased metabolism of Venlafaxine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [56]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Venlafaxine and Dasatinib. Myeloproliferative neoplasm [2A20] [67]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Venlafaxine and Prasugrel. Myocardial infarction [BA41-BA43] [67]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Venlafaxine and Vorapaxar. Myocardial infarction [BA41-BA43] [67]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Venlafaxine and Tirofiban. Myocardial infarction [BA41-BA43] [67]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Droperidol. Nausea/vomiting [MD90] [62]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Prochlorperazine. Nausea/vomiting [MD90] [62]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Venlafaxine and Palonosetron. Nausea/vomiting [MD90] [62]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Granisetron. Nausea/vomiting [MD90] [62]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Venlafaxine and Dolasetron. Nausea/vomiting [MD90] [62]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Venlafaxine and Ondansetron. Nausea/vomiting [MD90] [62]
E-2007 DMJDYNQ Moderate Antagonize the effect of Venlafaxine when combined with E-2007. Neuropathy [8C0Z] [69]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Entrectinib. Non-small cell lung cancer [2C25] [56]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Venlafaxine and Sibutramine. Obesity [5B80-5B81] [101]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Venlafaxine and Lorcaserin. Obesity [5B80-5B81] [102]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Venlafaxine and Dexfenfluramine. Obesity [5B80-5B81] [57]
Propylhexedrine DMTBW2O Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Propylhexedrine. Obesity [5B80-5B81] [66]
Chlorthalidone DM4DMBT Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Chlorthalidone. Oedema [MG29] [75]
Metolazone DMB39LO Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Metolazone. Oedema [MG29] [75]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Polythiazide. Oedema [MG29] [75]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Venlafaxine and Urea. Oesophagitis [DA24] [75]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Levomethadyl Acetate. Opioid use disorder [6C43] [63]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Venlafaxine and Lofexidine. Opioid use disorder [6C43] [62]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Venlafaxine and Diclofenac. Osteoarthritis [FA00-FA05] [67]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Venlafaxine and Naproxen. Osteoarthritis [FA00-FA05] [67]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Rucaparib. Ovarian cancer [2C73] [62]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Venlafaxine and Pentazocine. Pain [MG30-MG3Z] [57]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Venlafaxine and Dextropropoxyphene. Pain [MG30-MG3Z] [103]
Butorphanol DM5KYPJ Moderate Additive serotonergic effects by the combination of Venlafaxine and Butorphanol. Pain [MG30-MG3Z] [65]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Venlafaxine and Oxymorphone. Pain [MG30-MG3Z] [65]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Venlafaxine and Aspirin. Pain [MG30-MG3Z] [74]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Venlafaxine and Etodolac. Pain [MG30-MG3Z] [67]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Venlafaxine and Diflunisal. Pain [MG30-MG3Z] [67]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Venlafaxine and Ibuprofen. Pain [MG30-MG3Z] [67]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Venlafaxine and Nabumetone. Pain [MG30-MG3Z] [67]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Venlafaxine and Levorphanol. Pain [MG30-MG3Z] [65]
Hydromorphone DMHP21E Moderate Additive serotonergic effects by the combination of Venlafaxine and Hydromorphone. Pain [MG30-MG3Z] [65]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Venlafaxine and Dezocine. Pain [MG30-MG3Z] [65]
Codeine DMJX6ZG Moderate Additive serotonergic effects by the combination of Venlafaxine and Codeine. Pain [MG30-MG3Z] [65]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Venlafaxine and Nalbuphine. Pain [MG30-MG3Z] [65]
Buprenorphine DMPRI8G Moderate Additive serotonergic effects by the combination of Venlafaxine and Buprenorphine. Pain [MG30-MG3Z] [65]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Venlafaxine and Piroxicam. Pain [MG30-MG3Z] [67]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Venlafaxine and Meperidine. Pain [MG30-MG3Z] [57]
Oxycodone DMXLKHV Moderate Additive serotonergic effects by the combination of Venlafaxine and Oxycodone. Pain [MG30-MG3Z] [65]
Trimethadione DM0Q8MZ Moderate Antagonize the effect of Venlafaxine when combined with Trimethadione. Pancreatic cancer [2C10] [69]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Triclabendazole. Parasitic worm infestation [1F90] [62]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Venlafaxine and Safinamide. Parkinsonism [8A00] [58]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Venlafaxine and Rasagiline. Parkinsonism [8A00] [58]
Dopamine DMPGUCF Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Dopamine. Parkinsonism [8A00] [66]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Pimavanserin. Parkinsonism [8A00] [104]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Apomorphine. Parkinsonism [8A00] [62]
Abametapir DM2RX0I Moderate Decreased metabolism of Venlafaxine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [105]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Venlafaxine and Lindane. Pediculosis [1G00] [106]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Famotidine. Peptic ulcer [DA61] [56]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Venlafaxine and Macimorelin. Pituitary gland disorder [5A60-5A61] [107]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Venlafaxine and Choline salicylate. Postoperative inflammation [1A00-CA43] [67]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Venlafaxine and Ketorolac. Postoperative inflammation [1A00-CA43] [67]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Venlafaxine and Bromfenac. Postoperative inflammation [1A00-CA43] [67]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Venlafaxine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [56]
Ritodrine DM4V6RL Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Ritodrine. Preterm labour/delivery [JB00] [66]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Degarelix. Prostate cancer [2C82] [63]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Venlafaxine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [108]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Nilutamide. Prostate cancer [2C82] [63]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Enzalutamide. Prostate cancer [2C82] [63]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Venlafaxine caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [56]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Alfuzosin. Prostate hyperplasia [GA90] [62]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Levomepromazine. Psychotic disorder [6A20-6A25] [62]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Triflupromazine. Psychotic disorder [6A20-6A25] [62]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Venlafaxine and Treprostinil. Pulmonary hypertension [BB01] [67]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Venlafaxine and Epoprostenol. Pulmonary hypertension [BB01] [67]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Venlafaxine and Iloprost. Pulmonary hypertension [BB01] [67]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Sorafenib. Renal cell carcinoma [2C90] [62]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [109]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Venlafaxine and Meloxicam. Rheumatoid arthritis [FA20] [67]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Venlafaxine and Sulindac. Rheumatoid arthritis [FA20] [67]
Celecoxib DM6LOQU Moderate Decreased metabolism of Venlafaxine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [110]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Venlafaxine and Oxaprozin. Rheumatoid arthritis [FA20] [67]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Venlafaxine and Flurbiprofen. Rheumatoid arthritis [FA20] [67]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Venlafaxine and Fenoprofen. Rheumatoid arthritis [FA20] [67]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Venlafaxine and Indomethacin. Rheumatoid arthritis [FA20] [67]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Venlafaxine and Tolmetin. Rheumatoid arthritis [FA20] [67]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Quetiapine. Schizophrenia [6A20] [62]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Venlafaxine and Mesoridazine. Schizophrenia [6A20] [62]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Venlafaxine and Thioridazine. Schizophrenia [6A20] [62]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Venlafaxine and Iloperidone. Schizophrenia [6A20] [62]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Perphenazine. Schizophrenia [6A20] [62]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Chlorpromazine. Schizophrenia [6A20] [62]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Venlafaxine and Clozapine. Schizophrenia [6A20] [62]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Trifluoperazine. Schizophrenia [6A20] [62]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Risperidone. Schizophrenia [6A20] [62]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Venlafaxine and Amisulpride. Schizophrenia [6A20] [111]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Asenapine. Schizophrenia [6A20] [62]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Venlafaxine and Pimozide. Schizophrenia [6A20] [63]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Venlafaxine and Salicyclic acid. Seborrhoeic dermatitis [EA81] [74]
Norepinephrine DMOUC09 Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Norepinephrine. Sepsis [1G40-1G41] [66]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Vardenafil. Sexual dysfunction [HA00-HA01] [62]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Venlafaxine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [56]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Venlafaxine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [63]
Larotrectinib DM26CQR Moderate Decreased metabolism of Venlafaxine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [56]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and LEE011. Solid tumour/cancer [2A00-2F9Z] [56]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [62]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Venlafaxine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [62]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [63]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [62]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Venlafaxine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [63]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [62]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Venlafaxine and Warfarin. Supraventricular tachyarrhythmia [BC81] [67]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Venlafaxine and Ibutilide. Supraventricular tachyarrhythmia [BC81] [62]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Adenosine. Supraventricular tachyarrhythmia [BC81] [62]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Venlafaxine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [112]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Venlafaxine and Caplacizumab. Thrombocytopenia [3B64] [67]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Venlafaxine and Apixaban. Thrombosis [DB61-GB90] [67]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Venlafaxine and Cangrelor. Thrombosis [DB61-GB90] [67]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Venlafaxine and Brilinta. Thrombosis [DB61-GB90] [67]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Venlafaxine and Clopidogrel. Thrombosis [DB61-GB90] [67]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Lenvatinib. Thyroid cancer [2D10] [62]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Venlafaxine and Papaverine. Tonus and reflex abnormality [MB47] [113]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Tizanidine. Tonus and reflex abnormality [MB47] [62]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Tacrolimus. Transplant rejection [NE84] [62]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Astemizole. Vasomotor/allergic rhinitis [CA08] [62]
Xylometazoline DMKV32D Moderate Increased risk of rapid heart rate by the combination of Venlafaxine and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [66]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Venlafaxine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [114]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Venlafaxine and Betrixaban. Venous thromboembolism [BD72] [67]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Venlafaxine and Procainamide. Ventricular tachyarrhythmia [BC71] [62]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Propafenone. Ventricular tachyarrhythmia [BC71] [62]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Venlafaxine and Flecainide. Ventricular tachyarrhythmia [BC71] [62]
⏷ Show the Full List of 340 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Cetostearyl alcohol E00353 62238 Emollient; Emulsifying agent; Viscosity-controlling agent
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Sodium hydroxide E00234 14798 Alkalizing agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Ethyl cellulose E00699 Not Available Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
⏷ Show the Full List of 50 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Venlafaxine 150 mg tablet 150 mg 24 HR Extended Release Oral Tablet Oral
Venlafaxine 225 mg tablet 225 mg 24 HR Extended Release Oral Tablet Oral
Venlafaxine 37.5 mg tablet 37.5 mg 24 HR Extended Release Oral Tablet Oral
Venlafaxine 75 mg tablet 75 mg 24 HR Extended Release Oral Tablet Oral
Venlafaxine 37.5 mg capsule 37.5 mg 24 HR Extended Release Oral Capsule Oral
Venlafaxine 75 mg capsule 75 mg 24 HR Extended Release Oral Capsule Oral
Venlafaxine 150 mg capsule 150 mg 24 HR Extended Release Oral Capsule Oral
Venlafaxine 37.5 mg capsule 37.5 mg 24 HR Extended Release Capsule Oral
Venlafaxine 75 mg capsule 75 mg 24 HR Extended Release Capsule Oral
Venlafaxine 150 mg capsule 150 mg 24 HR Extended Release Capsule Oral
Venlafaxine 100 mg tablet 100 mg Oral Tablet Oral
Venlafaxine 25 mg tablet 25 mg Oral Tablet Oral
Venlafaxine 37.5 mg tablet 37.5 mg Oral Tablet Oral
Venlafaxine 50 mg tablet 50 mg Oral Tablet Oral
Venlafaxine 75 mg tablet 75 mg Oral Tablet Oral
Venlafaxine Hydrochloride eq 12.5mg base tablet eq 12.5mg base Tablet Oral
Venlafaxine Hydrochloride eq 37.5mg base extended release capsule eq 37.5mg base Extended Release Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7321).
2 Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-36.
3 Opilon monograph
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
12 O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
30 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
31 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
32 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
33 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
34 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
35 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
36 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
37 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
38 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
39 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
40 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
41 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
42 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
43 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
44 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
45 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
46 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
47 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
48 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
49 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
50 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
51 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
52 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
53 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
54 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
55 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
56 Cerner Multum, Inc. "Australian Product Information.".
57 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
58 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
59 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
60 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
61 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
62 Canadian Pharmacists Association.
63 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
64 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
65 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
66 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
67 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
68 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
69 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
70 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
71 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
72 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
73 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
74 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
75 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
76 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
78 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
79 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
81 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
82 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
83 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
84 Product Information. Effexor (venlafaxine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
85 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
86 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
87 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
88 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
89 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
90 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
91 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
92 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
93 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
94 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
95 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
96 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
97 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
98 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
99 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
100 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
101 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
102 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
103 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
104 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
105 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
106 Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2. [PMID: 10974795]
107 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
108 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
109 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
110 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
111 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
112 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
113 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
114 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.